Signaling of DNA damage is not sufficient to induce p53 response: (Re)activation of wt p53 protein strongly depends on cellular context

Journal of Cellular Biochemistry

Volumn 103, Issue 5, 2008, Pages 1607-1620

  Wȩsierska Ga̧dek, Józefa ^a   Gueorguieva, Marieta ^a   Komina, Oxana ^a   Schmid, Gerald ^a,b   Kramer, Matthias P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

Author keywords

ATM kinase; Cell cycle arrest; Checkpoints; DNA breaks; Single cell gel electrophoresis

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; DOXORUBICIN; HISTONE H2AX; METHYLNITRONITROSOGUANIDINE; NIBRIN; PROTEIN E6; PROTEIN P53;

ARTICLE; CELL STRAIN MCF 7; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA STRAND BREAKAGE; GENOTOXICITY; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE PROTEINS; DNA DAMAGE; DOXORUBICIN; HELA CELLS; HUMANS; METHYLNITRONITROSOGUANIDINE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UP-REGULATION;

EID: 41749096110     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21548     Document Type: Article

References (54)

1. Abraham RT. 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15(17):2177-2196.
2. Adamson AW, Kim WJ, Shangary S, Baskaran R, Brown KD. 2002. ATM is activated in response to N-methyl-N′-nitro-N-nitrosoguanidine-induced DNA alkylation. J Biol Chem 277(41):38222-38229.
3. Allen KL, Tschantz DR, Awad KS, Lynch WP, Delucia AL. 2007. A plant lignan, 3′-O-Methyl-Nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells. Mol Carcinog 46(7):564-575.
4. Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268(10):2764-2772.
5. Bai L, Wei L, Wang J, Li X, He P. 2006. Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells. Int J Gynecol Cancer 16(2):718-729.
6. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, et al. 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (New York, NY) 281(5383):1674-1677.
7. Bernstein C, Bernstein H, Payne CM, Garewal H. 2002. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mut Res 511(2):145-178.
8. Butz K, Geisen C, Ullmann A, Spitkovsky D, Hoppe-Seyler F. 1996. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: Repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 68(4):506-513.
9. Camus S, Higgins M, Lane DP, Lain S. 2003. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett 536(1-3):220-224.
10. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP. 2007. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 26(28):4059-4070.
11. Courtete J, Sibler AP, Zeder-Lutz G, Dalkara D, Oulad-Abdelghani M, Zuber G, Weiss E. 2007. Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA. Mol Cancer Ther 6(6):1728-1735.
12. Durocher D, Jackson SP. 2001. DNA-PK, ATM and ATR as sensors of DNA damage: Variations on a theme? Curr Opin Cell Biol 13(2):225-231.
13. Eadie JS, Conrad M, Toorchen D, Topal MD. 1984. Mechanism of mutagenesis by O6-methylguanine. Nature 308(5955):201-203.
14. Fritsche M, Haessler C, Brandner G. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8(2):307-318.
15. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. 1998. Mdm2 association with p53 targets its ubiquitination. Oncogene 17(19):2543-2547.
16. Green CM, Erdjument-Bromage H, Tempst P, Lowndes NF. 2000. A novel Rad24 checkpoint protein complex closely related to replication factor C. Curr Biol 10(1):39-42.
17. Haines DS, Landers JE, Engle LJ, George DL. 1994. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 14(2):1171-1178.
18. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387(6630):296-299.
19. Helma C, Uhl M. 2000. A public domain image-analysis program for the single-cell gel-electrophoresis (comet) assay. Mut Res 466(1):9-15.
20. Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. 2001. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98(3):1218-1223.
21. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML. 2002. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4(1):1-10.
22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51(23 Pt 1):6304-6311.
23. Kleihues P, Margison GP. 1974. Carcinogenicity of N-methyl-N-nitrosourea: Possible role of excision repair of O6-methylguanine from DNA. J Natl Cancer Inst 53(6):1839-1841.
24. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387(6630):299-303.
25. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88(3):323-331.
26. Loveless A. 1969. Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides. Nature 223(5202):206-207.
27. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237-1245.
28. O'Connell MJ, Walworth NC, Carr AM. 2000. The G2-phase DNA-damage checkpoint. Trends Cell Biol 10(7):296-303.
29. Offer H, Wolkowicz R, Matas D, Blumenstein S, Livneh Z, Rotter V. 1999. Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 450(3):197-204.
30. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362(6423):857-860.
31. Oren M. 1999. Regulation of the p53 tumor suppressor protein. J Biol Chem 274(51):36031-36034.
32. Parra M, Jardi M, Koziczak M, Nagamine Y, Munoz-Canoves P. 2001. p53 Phosphorylation at serine 15 is required for transcriptional induction of the plasminogen activator inhibitor-1 (PAI-1) gene by the alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine. J Biol Chem 276 (39):36303-36310.
33. Pauli TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. 2000. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10(15):886-895.
34. Petrini JH. 1999. The mammalian Mre11-Rad50-nbs1 protein complex: Integration of functions in the cellular DNA-damage response. Am J Hum Genet 64(5):1264-1269.
35. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. 1998. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58(19):4375-4382.
36. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6):1129-1136.
37. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3):495-505.
38. Seo YR, Jung HJ. 2004. The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). Exp Mol Med 36(6):505-509.
39. Shiloh Y. 1997. Ataxia-telangiectasia and the Nijmegen breakage syndrome: Related disorders but genes apart. Annu Rev Genet 31:635-662.
40. Shulman LN. 1993. The biology of alkylating-agent cellular injury. Hematol/Oncol ClinNorth Am 7(2):325-335.
41. Singer B. 1975. The chemical effects of nucleic acid alkylation and their relation to mutagenesis and carcinogenesis. Prog Nucleic Acid Res Mol Biol 15(0):219-284.
42. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175(1):184-191.
43. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35(3):206-221.
44. Vidal B, Parra M, Jardi M, Saito S, Appella E, Munoz-Canoves P. 2005. The alkylating carcinogen N-methyl-N′-nitro-N-nitrosoguanidine activates the plasminogen activator inhibitor-1 gene through sequential phosphorylation of p53 by ATM and ATR kinases. Throm Haemos 93(3):584-591.
45. Viktorsson K, De Petris L, Lewensohn R. 2005. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331(3):868-880.
46. Vindelov LL, Christensen IJ, Nissen NI. 1983. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3(5):323-327.
47. Wesierska-Gadek J, Schmid G. 2000. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80(1):85-103.
48. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. 2002. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int J Cancer 101(2):128-136.
49. Wesierska-Gadek J, Gueorguieva M, Schloffer D, Uhl M, Wojciechowski J. 2003. Non-apoptogenic killing of hela cervical carcinoma cells after short exposure to the alkylating agent N-methyl-N′-nitro-N-nitrosoguanidine (MNNG). J Cell Biochem 89(6):1222-1234.
50. Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A. 2004. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64(13):4487-4497.
51. Wesierska-Gadek J, Schmitz ML, Ranftler C. 2007. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100(4):865-874.
52. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal G. 2002. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419(6909):853-857.
53. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. 1995. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 23(14):2584-2592.
54. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP, Xiao ZX. 2002. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419(6909):849-853.